Gilead reports additional Phase III data from HIV switching trial of Biktarvy

Gilead Sciences Inc. (NASDAQ:GILD) reported additional data from the Phase III GS-US-380-1844 trial in 563 virologically suppressed adults with HIV-1 infection showing that switching from either Tivicay dolutegravir plus abacavir/lamivudine or Triumeq dolutegravir/abacavir/lamivudine to

Read the full 340 word article

User Sign In